- Home
- ASTC vs MYNZ Comparison
ASTC vs MYNZ Comparison
Compare ASTC & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASTC
- MYNZ
- Stock Information
- Founded
- ASTC 1984
- MYNZ 2021
- Country
- ASTC United States
- MYNZ Germany
- Employees
- ASTC N/A
- MYNZ N/A
- Industry
- ASTC Biotechnology: Laboratory Analytical Instruments
- MYNZ Biotechnology: Pharmaceutical Preparations
- Sector
- ASTC Industrials
- MYNZ Health Care
- Exchange
- ASTC Nasdaq
- MYNZ Nasdaq
- Market Cap
- ASTC 8.6M
- MYNZ 7.9M
- IPO Year
- ASTC 1995
- MYNZ 2021
- Fundamental
- Price
- ASTC $5.00
- MYNZ $1.61
- Analyst Decision
- ASTC
- MYNZ Buy
- Analyst Count
- ASTC 0
- MYNZ 2
- Target Price
- ASTC N/A
- MYNZ $14.00
- AVG Volume (30 Days)
- ASTC 4.8K
- MYNZ 107.2K
- Earning Date
- ASTC 05-13-2025
- MYNZ 10-21-2025
- Dividend Yield
- ASTC N/A
- MYNZ N/A
- EPS Growth
- ASTC N/A
- MYNZ N/A
- EPS
- ASTC N/A
- MYNZ N/A
- Revenue
- ASTC $903,000.00
- MYNZ $893,991.00
- Revenue This Year
- ASTC N/A
- MYNZ $26.06
- Revenue Next Year
- ASTC N/A
- MYNZ $4.97
- P/E Ratio
- ASTC N/A
- MYNZ N/A
- Revenue Growth
- ASTC N/A
- MYNZ N/A
- 52 Week Low
- ASTC $4.71
- MYNZ $1.30
- 52 Week High
- ASTC $10.83
- MYNZ $16.04
- Technical
- Relative Strength Index (RSI)
- ASTC 44.52
- MYNZ 44.61
- Support Level
- ASTC $4.94
- MYNZ $1.70
- Resistance Level
- ASTC $5.38
- MYNZ $1.79
- Average True Range (ATR)
- ASTC 0.22
- MYNZ 0.11
- MACD
- ASTC 0.02
- MYNZ -0.00
- Stochastic Oscillator
- ASTC 38.16
- MYNZ 3.33
About ASTC Astrotech Corporation (DE)
Astrotech Corp is a science and technology development company. The firm invents, acquires, and commercializes technological innovations sourced from internal research, universities, laboratories, and research institutions. The 1st Detect develops, manufactures, and sells chemical analyzers for use in the airport security, military, and breath analysis markets. AgLAB develops a series of mass spectrometers for use in the agriculture market.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.